Matthew Holderfield
Revolution Medicines (United States)
ORCID: 0000-0001-8474-3220Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 7 papers. Top paper: “Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy”.
Bianca J. Lee, Jingjing Jiang, Aidan C.A. Tomlinson, Kyle J. Seamon, Alessia Mira +48 more
Jingjing Jiang, Tanner C. Dalton, Álvaro Curiel‐García, A. Cole Edwards, Yingyun Wang +61 more
Kanika Sharma, Melissa Hoffman, Eric Kuhn, Lei Zhao, Alexandra R. Cocco +19 more
Matthew Holderfield, Bianca Lee, Jingjing Jiang, Aidan Tomlinson, Kyle Seamon +44 more
Jingjing Jiang, Alvaro Curiel-Garcia, Yingyun Wang, Bianca J. Lee, Margo Orlen +42 more
Emmiliisa Vuorinen, Maria Abreu Blanco, Qi Wang, Ville Eskonen, William Gillette +4 more
Nicole Nasholm, Chiara Ambrogio, Anthony N. Milin, Yang Liu, Elsa Quintana +48 more